{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:26Z","timestamp":1791389486559,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s13555-023-00889-0","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T17:08:33Z","timestamp":1673629713000},"page":"843-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib\u2014A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata"],"prefix":"10.1007","volume":"13","author":[{"given":"Kinga","family":"Ko\u0142cz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-0529","authenticated-orcid":false,"given":"Magdalena","family":"\u017bychowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Sawi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"889_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.annder.2022.03.006","volume":"149","author":"J Seneschal","year":"2022","unstructured":"Seneschal J, Boniface K, Jacquemin C. Alopecia areata: recent advances and emerging therapies. Ann Dermatol Venereol. 2022;149:222\u20137.","journal-title":"Ann Dermatol Venereol"},{"key":"889_CR2","first-page":"397","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"889_CR3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdv.17187","volume":"35","author":"A Wa\u015bkiel-Burnat","year":"2021","unstructured":"Wa\u015bkiel-Burnat A, Ko\u0142odziejak M, Sikora M, et\u00a0al. Therapeutic management in paediatric alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2021;35:1299\u2013308.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"889_CR4","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.3390\/ijms22052618","volume":"22","author":"R Kageyama","year":"2021","unstructured":"Kageyama R, Ito T, Hanai S, et\u00a0al. Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci. 2021;22:2618.","journal-title":"Int J Mol Sci"},{"key":"889_CR5","doi-asserted-by":"publisher","first-page":"13023","DOI":"10.1111\/dth.13023","volume":"32","author":"C Patruno","year":"2019","unstructured":"Patruno C, Napolitano M, Ferrillo M, Fabbrocini G. Dupilumab and alopecia: a Janus effect. Dermatol Ther. 2019;32:13023.","journal-title":"Dermatol Ther"},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/jid.2012.129","volume":"132","author":"D Jagielska","year":"2012","unstructured":"Jagielska D, Redler S, Brockschmidt FF, et\u00a0al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol. 2012;132:2192\u20137.","journal-title":"J Invest Dermatol"},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","volume":"166","author":"AG Messenger","year":"2012","unstructured":"Messenger AG, McKillop J, Farrant P, et\u00a0al. British Association of Dermatologists\u2019 guidelines for the management of alopecia areata. Br J Dermatol. 2012;166:916\u201326.","journal-title":"Br J Dermatol"},{"key":"889_CR8","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et\u00a0al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomized controlled phase 3 trials. Lancet. 2021;397:2151\u201368.","journal-title":"Lancet"},{"key":"889_CR9","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1002\/ccr3.2484","volume":"7","author":"RN Ferreira","year":"2019","unstructured":"Ferreira RN, Ferreira SB, Scheinberg MA. An excellent response to tofacitinib in a Brazillian adolescent patient with alopecia areata: a case report and a review of the literature. Clin Case Rep. 2019;7:2539\u201342.","journal-title":"Clin Case Rep"},{"key":"889_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, et\u00a0al. The alopecia areata consensus of experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.23736\/S0392-0488.19.06458-7","volume":"154","author":"A Rossi","year":"2019","unstructured":"Rossi A, Muscianese M, Piraccini BM, et\u00a0al. Italian guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol. 2019;154:609\u201323.","journal-title":"G Ital Dermatol Venereol"},{"key":"889_CR12","first-page":"24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2:24137.","journal-title":"JAKSTAT"},{"key":"889_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et\u00a0al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043\u20139.","journal-title":"Nat Med"},{"key":"889_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","volume":"77","author":"CB Bayart","year":"2017","unstructured":"Bayart CB, DeNiro KL, Brichta L, et\u00a0al. Topical Janus kinase inhibitor for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77:167\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et\u00a0al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399.","journal-title":"N Engl J Med"},{"key":"889_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Ko J, Forman S, et\u00a0al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85:847\u201353.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","volume":"87","author":"B King","year":"2022","unstructured":"King B, Mesinkovska N, Mirmirani P, et\u00a0al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87:306\u201313.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR18","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, et\u00a0al. Titlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149:1318\u201328.","journal-title":"J Allergy Clin Immunol"},{"key":"889_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","volume":"78","author":"E Putterman","year":"2018","unstructured":"Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis and alopecia universalis. J Am Acad Dermatol. 2018;78:1207\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L, et\u00a0al. Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor Baricitinib. EBioMedicine. 2015;2:351\u20135.","journal-title":"EBioMedicine"},{"key":"889_CR21","first-page":"15845","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu T, Li S, Tang S, Lin P, et\u00a0al. Efficay and safety of baricitinib in patients with refractory alopecia areata. Dermatol Ther. 2022;19:15845.","journal-title":"Dermatol Ther"},{"key":"889_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","volume":"80","author":"LY Liu","year":"2019","unstructured":"Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80:566\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","volume":"6","author":"DM Peterson","year":"2020","unstructured":"Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep. 2020;6:257\u20139.","journal-title":"JAAD Case Rep"},{"key":"889_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","volume":"76","author":"BG Craiglow","year":"2017","unstructured":"Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76:29\u201331.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jaad.2016.11.038","volume":"76","author":"L Castelo-Soccio","year":"2017","unstructured":"Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76:754\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR26","first-page":"914","volume":"17","author":"L Brown","year":"2018","unstructured":"Brown L, Skopit S. An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review. J Drugs Dermatol. 2018;17:914\u20137.","journal-title":"J Drugs Dermatol"},{"key":"889_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1203475418760512","volume":"22","author":"NU Patel","year":"2018","unstructured":"Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg. 2018;22:439\u201342.","journal-title":"J Cutan Med Surg"},{"key":"889_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jdcr.2019.02.007","volume":"5","author":"AL Rachubinski","year":"2019","unstructured":"Rachubinski AL, Estrada BE, Norris D, et\u00a0al. Janus kinase inhibition in down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep. 2019;5:365\u20137.","journal-title":"JAAD Case Rep"},{"key":"889_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2018.08.041","volume":"80","author":"BG Craiglow","year":"2019","unstructured":"Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019;80:568\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR30","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jaad.2018.12.041","volume":"80","author":"YX Dai","year":"2019","unstructured":"Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol. 2019;80:1164\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/pde.14422","volume":"38","author":"R Jerjen","year":"2021","unstructured":"Jerjen R, Meah N, De Carvalho LT, Wall D, Eisman S, Sinclair R. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study. Pediatr Dermatol. 2021;38:103\u20138.","journal-title":"Pediatr Dermatol"},{"key":"889_CR32","first-page":"15871","volume":"30","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed H, Abdulla N, Al-Obaidli A, et\u00a0al. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: a prospective, open-label, single-center study in Asian Arab population. Dermatol Ther. 2022;30:15871.","journal-title":"Dermatol Ther"},{"key":"889_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/pde.14855","volume":"39","author":"J Kibbie","year":"2022","unstructured":"Kibbie J, Kines K, Norris D, Dunnick CA. Oral tofacitinib for the treatment of alopecia areata in pediatric patients. Pediatr Dermatol. 2022;39:31\u20134.","journal-title":"Pediatr Dermatol"},{"key":"889_CR34","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1111\/jocd.14726","volume":"21","author":"K Sardana","year":"2022","unstructured":"Sardana K, Mathhanach SR, Gupta P. Pertinent role of maintenance dose of oral tofacitinib in a child with alopecia totalis with a 25-year follow-up on low dose. J Cosmet Dermatol. 2022;21:4091\u20134.","journal-title":"J Cosmet Dermatol."},{"key":"889_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jaad.2021.02.071","volume":"86","author":"PL McKenzie","year":"2022","unstructured":"McKenzie PL, Castelo-Soccio L. Alopecia areata flare patterns in children and young adults while on systemic tofacitinib. J Am Acad Dermatol. 2022;86:683\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"889_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et\u00a0al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158:404\u201313.","journal-title":"JAMA Dermatol"},{"key":"889_CR37","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et\u00a0al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169\u201381.","journal-title":"Lancet"},{"key":"889_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/DER.0000000000000780","volume":"32","author":"A Gambardella","year":"2021","unstructured":"Gambardella A, Licata G, Calabrese G, De Rosa A, Alfano R, Argenziano G. Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata. Dermatitis. 2021;32:85\u20136.","journal-title":"Dermatitis"},{"key":"889_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16342","author":"N Gori","year":"2022","unstructured":"Gori N, Cappilli S, Di Stefani A, Tassone F, Chiricozzi A, Peris K. Assessment of alopecia areata universalis successfully treated with upadacitinib. Int J Dermatol. 2022. https:\/\/doi.org\/10.1111\/ijd.16342.","journal-title":"Int J Dermatol"},{"key":"889_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ijd.16316","volume":"61","author":"L Asfour","year":"2022","unstructured":"Asfour L, Getsos Colla T, Moussa A, Sinclair RD. Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib. Int J Dermatol. 2022;61:416\u20137.","journal-title":"Int J Dermatol"},{"key":"889_CR41","doi-asserted-by":"publisher","first-page":"15346","DOI":"10.1111\/dth.15346","volume":"35","author":"M Cantelli","year":"2022","unstructured":"Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022;35:15346.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00889-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00889-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00889-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T03:43:39Z","timestamp":1677901419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00889-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00889-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}